Peter Kufer,Dirk Nagorsen,Juergen Scheele,Gerhard Zugmaier,Matthias Klinger,Patrick Hoffmann,Virginie Naegele,Elaine-Pashupati Dopfer
申请号：
US14176091
公开号：
US09688760B2
申请日:
2014.02.08
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab； minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids； and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.
